Follicular lymphoma often responds to treatment and then relapses, requiring further treatment. Rituximab plus chemotherapy is the standard treatment for follicular lymphoma, and is often followed by rituximab alone to maintain remission. In this study, researchers want to see if rituximab plus the drug lenalidomide followed by rituximab maintenance therapy is more effective than the standard treatment for patients with previously untreated follicular lymphoma.
Lenalidomide is approved for the treatment of a cancer called multiple myeloma and for myelodysplastic syndromes, but its use for treating follicular lymphoma is considered investigational. In prior clinical trials of previously treated patients, however, the combination of rituximab and lenalidomide was highly active. Lenalidomide alters the immune system and may interfere with the tiny blood vessels that support tumor growth.
Patients in this study will be randomly assigned to receive rituximab plus standard chemotherapy or rituximab plus lenalidomide. Patients will then have maintenance therapy with rituximab alone or rituximab plus lenalidomide.